AI assistant
Sending…
IMMUCELL CORP /DE/ — Director's Dealing 2004
Feb 17, 2004
34519_dirs_2004-02-17_61a5bffc-6728-43f8-90fc-20027d44931a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IMMUCELL CORP /DE/ (ICCC)
CIK: 0000811641
Period of Report: 2004-02-12
Reporting Person: ROTHSCHILD JONATHAN E (Director, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2004-02-12 | Common Stock, par value $0.10 per share | P | 400 | $4.22 | Acquired | 361060 | Direct |
| 2004-02-12 | Common Stock, par value $0.10 per share | P | 300 | $4.23 | Acquired | 361360 | Direct |
| 2004-02-12 | Common Stock, par value $0.10 per share | P | 800 | $4.21 | Acquired | 362160 | Direct |
| 2004-02-12 | Common Stock, par value $0.10 per share | P | 400 | $4.22 | Acquired | 362560 | Direct |
| 2004-02-12 | Common Stock, par value $0.10 per share | P | 400 | $4.23 | Acquired | 362960 | Direct |
| 2004-02-13 | Common Stock, par value $0.10 per share | P | 300 | $4.19 | Acquired | 363260 | Direct |
| 2004-02-13 | Common Stock, par value $0.10 per share | P | 200 | $4.19 | Acquired | 363460 | Direct |
| 2004-02-13 | Common Stock, par value $0.10 per share | P | 600 | $4.22 | Acquired | 364060 | Direct |
| 2004-02-13 | Common Stock, par value $0.10 per share | P | 800 | $4.20 | Acquired | 364860 | Direct |
| 2004-02-13 | Common Stock, par value $0.10 per share | P | 400 | $4.16 | Acquired | 365260 | Direct |
| 2004-02-17 | Common Stock, par value $0.10 per share | P | 600 | $4.25 | Acquired | 365860 | Direct |
Footnotes
F1: These shares were acquired by Arterio, Inc., a company solely owned by Mr. Rothschild.
More from IMMUCELL CORP /DE/
Regulatory Filings
2026
May 14
Annual Report
2026
May 13
Regulatory Filings
2026
May 8
Proxy Solicitation & Information Statement
2026
Apr 24
Regulatory Filings
2026
Apr 14
Regulatory Filings
2026
Apr 14
Regulatory Filings
2026
Apr 8
Annual Report
2026
Mar 30
Director's Dealing
2026
Mar 25
Director's Dealing
2026
Mar 23